Rhizen Pharmaceuticals S.A. Announces Publication of Clinical Data from the Phase I/Ib study of Tenalisib (RP6530) in Patients with Relapsed/Refractory T-Cell Lymphoma (TCL)
September 24, 2020 14:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced the publication of the results from the Phase I/Ib study of Tenalisib (RP6530), the...
Global Anticancer Drug Market- Providing Targeted Treatment Solutions to Cancer Patients Using Nano-Technology Enhancing the Way to Cure the Disease, Reach USD 145.2 Billion By 2023: Energias Market Research Pvt. Ltd.
February 08, 2018 06:32 ET
|
Energias Market Research
NEW YORK, Feb. 08, 2018 (GLOBE NEWSWIRE) --
Global Anticancer Drug market size is expected to reach USD 145.2 Billion in 2023, at a CAGR of 6.7% from 2017 to 2023. The growth of the...